Autopsy report · NCT03827096

Utilization of Autologous Mesenchymal Cells in Posterolateral Spinal Fusion in Degenerative Spine Disease

“Primary endpoint (Safety) has been achieved”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 years 5 months after it had already started.
• Ran for about 3 years 4 months before it stopped.
• 10 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Bioinova, s.r.o.

Sponsor type

Industry

Conditions

Degenerative Disc Disease

Interventions

Suspension of human autologous MSC 3P in 1.5 ml

Participants

10

Trials that died the same way

• A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer
  “Primary (safety) endpoint reached” (90% match in meaning)
• Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms
  “Primary Endpoint met” (76% match in meaning)
• Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)
  “Primary endpoint not achieved” (70% match in meaning)
• Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer
  “primary endpoint was not met” (68% match in meaning)
• CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
  “Primary Endpoint not met” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.